Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962408 | 0.83 | CYP2C19 (0.50) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL560994 | 0.82 | CYP2C19 (0.57) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL28944425 | 0.82 | CYP2C19 (0.57) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL7903413 | 0.82 | CYP2C19 (0.57) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL560995 | 0.82 | CYP2C19 (0.57) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL21698075 | 0.77 | CYP2C19 (0.52) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL15689522 | 0.77 | CYP2C19 (0.52) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL9906171 | 0.77 | CYP2C19 (0.52) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL26917 | 0.77 | CYP2C19 (0.55) | CYP2C19EGFRMAOBGLATDP1 | |
| SCHEMBL6286942 | 0.77 | CYP2C19 (0.55) | CYP2C19EGFRMAOBGLATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8198445-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113786-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | CYP2C19 2417/4885EGFR 2357/4885MAOB 1950/4885 |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | CYP2C19 2417/4885EGFR 2357/4885MAOB 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.